Using Genomics to Improve Pigmented Lesion Management & Health Outcomes

Main Article Content

Clay Cockerell
Roger Ceilley
Mark Lebwohl
Darrell Rigel


genomics, biopsy, access to care


Abstract not available. 


1. Anderson AM, Matsumoto M, Saul MI, Secrest AM, Ferris LK. Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System. JAMA Dermatol. May 1 2018;154(5):569-573. doi:10.1001/jamadermatol.2018.0212

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7-33. doi:

3. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. Jan 2017;76(1):114-120 e2. doi:10.1016/j.jaad.2016.07.038

4. Data on file. DermTech, Inc. La Jolla, California.

5. Hornberger J, Siegel DM. Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions. JAMA Dermatol. Sep 1 2018;154(9):1025-1031. doi:10.1001/jamadermatol.2018.1764

6. Skelsey M, Brouha B, Rock J, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. SKIN The Journal of Cutaneous Medicine. 2021;5(5):512-523.

7. Lott JP, Boudreau DM, Barnhill RL, et al. Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatol. Jan 1 2018;154(1):24-29. doi:10.1001/jamadermatol.2017.4060

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>